ArticleAntimicrobial agents and chemotherapy2018
The Orotomide Olorofim Is Efficacious in an Experimental Model of Central Nervous System Coccidioidomycosis.
Article in Antimicrobial agents and chemotherapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 1 synthesis or guideline pooled it, 74 citations in OpenAlex.
- Talaromyces marneffei, Coccidioides species, and Paracoccidioides species-a systematic review to inform the World Health Organization priority list of fungal pathogens.Medical mycology · 2024Pooled it
- In Vitro Evaluation of Olorofim and Amphotericin B Combination Therapy AgainstJournal of fungi (Basel, Switzerland) · 2026Article
- Drug-Induced Liver Injury From a Novel Antifungal - Olorofim.ACG case reports journal · 2026Article
- Lipid-Based Drug Delivery Systems as Emerging Tools to Overcome Antifungal Resistance.International journal of molecular sciences · 2026Review
- The tissue distribution and pharmacokinetics of [14C]-olorofim following intravenous dosing in the rat.The Journal of antimicrobial chemotherapy · 2026Article
- The next-generation polyene EL219 is efficacious in an experimental model of central nervous system coccidioidomycosis caused byAntimicrobial agents and chemotherapy · 2026Article
- Successful Control of RefractoryOpen forum infectious diseases · 2026Article
- Cerebral Aspergillosis: Diagnostic Challenges, Therapeutic Strategies, and Future Research.CNS drugs · 2026Review
- Drug Discovery and Repurposing forJournal of fungi (Basel, Switzerland) · 2025Review
- Olorofim activity against multidrug-resistantAntimicrobial agents and chemotherapy · 2025Article
- Case Commentary: Successful use of olorofim for the treatment of multi-drug-resistantAntimicrobial agents and chemotherapy · 2025Article
- Pearls and Pitfalls of Intrathecal Amphotericin B Therapy for Refractory Coccidioidal Meningitis in Children: An Illustrative Pediatric Case Series.The Pediatric infectious disease journal · 2025Article
- Next-generation antifungal drugs: Mechanisms, efficacy, and clinical prospects.Acta pharmaceutica Sinica. B · 2025Review
- Coccidioidomycosis: a growing global concern.The Journal of antimicrobial chemotherapy · 2025Review
- Olorofim demonstratesAntimicrobial agents and chemotherapy · 2025Article
- Review
- The evolution of antifungal therapy: Traditional agents, current challenges and future perspectives.Current research in microbial sciences · 2025Review
- The Significance of Mono- and Dual-Effective Agents in the Development of New Antifungal Strategies.Chemical biology & drug design · 2025Review
- Evaluation of nikkomycin Z with frequent oral administration in an experimental model of central nervous system coccidioidomycosis.Microbiology spectrum · 2024Article
- Novel antifungals and treatment approaches to tackle resistance and improve outcomes of invasive fungal disease.Clinical microbiology reviews · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
Olorofim (formerly F901318) is an advanced analog of the orotomide class that inhibits fungal pyrimidine biosynthesis. We evaluated the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.